Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy.

AstraZeneca1 个研究点分布在 1 个国家目标入组 1,940 人开始时间: 2007年9月最近更新: 2010年8月19日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 1,940
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•diagnosis of essential hypertension (mild or moderate as defined in European Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected

排除标准

•Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC

研究者

发起方

AstraZeneca

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

已完成

3 期

Telmisartan 80mg Non-responder TrialHypertension

NCT01222520Boehringer Ingelheim174

已完成

不适用

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk HypertensivesObesityHypertension

NCT00539487Boehringer Ingelheim5,827

已完成

不适用

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"Hypertension

NCT02166697Takeda14,151

已完成

3 期

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention TrialHypertension

NCT00227318AstraZeneca1,000

已完成

2 期

Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension PatientsHypertension

NCT00923611Boryung Pharmaceutical Co., Ltd182